Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
Roivant (Nasdaq: ROIV) has announced it will host a live conference call and webcast on Thursday, August 8, 2024, at 8:00 a.m. ET to report its financial results for the first quarter ended June 30, 2024, and provide a business update. Interested parties can register for the conference call online. The presentation and webcast details will be available in the Investors section of Roivant's website under 'Events & Presentations'. An archived version of the webcast will be accessible on the company's website after the conference call concludes.
Roivant (Nasdaq: ROIV) ha annunciato che ospiterà una conference call e un webcast dal vivo il giovedì 8 agosto 2024, alle 8:00 ET per riportare i suoi risultati finanziari per il primo trimestre chiuso il 30 giugno 2024 e fornire un aggiornamento aziendale. Le parti interessate possono registrarsi per la conference call online. I dettagli della presentazione e del webcast saranno disponibili nella sezione Investitori del sito web di Roivant sotto 'Eventi e Presentazioni'. Una versione archiviata del webcast sarà accessibile sul sito dell'azienda dopo la conclusione della conference call.
Roivant (Nasdaq: ROIV) ha anunciado que realizará una llamada de conferencia en vivo y un webcast el jueves 8 de agosto de 2024, a las 8:00 a.m. ET para informar sobre sus resultados financieros del primer trimestre finalizado el 30 de junio de 2024 y proporcionar una actualización del negocio. Las partes interesadas pueden registrarse para la llamada de conferencia en línea. Los detalles de la presentación y el webcast estarán disponibles en la sección de Inversores del sitio web de Roivant bajo 'Eventos y Presentaciones'. Una versión archivada del webcast será accesible en el sitio de la empresa después de que concluya la llamada de conferencia.
로이반트 (Nasdaq: ROIV)는 2024년 8월 8일 목요일 오전 8시(ET)에 실시간 컨퍼런스 콜 및 웹캐스트를 개최할 것이라고 발표했습니다. 이 자리에서 2024년 6월 30일 종료된 첫 분기의 재무 결과를 보고하고 비즈니스 업데이트를 제공합니다. 관심 있는 분들은 온라인으로 컨퍼런스 콜에 등록할 수 있습니다. 발표 및 웹캐스트 관련 정보는 로이반트 웹사이트의 투자자 섹션 '이벤트 및 발표'에서 확인할 수 있습니다. 컨퍼런스 콜이 종료된 후 회사 웹사이트에서 웹캐스트의 보관 버전도 접속할 수 있습니다.
Roivant (Nasdaq: ROIV) a annoncé qu'il organisera une conférence téléphonique en direct et un webinaire le jeudi 8 août 2024, à 8h00 ET pour présenter ses résultats financiers pour le premier trimestre clos le 30 juin 2024 et fournir une mise à jour sur l'entreprise. Les parties intéressées peuvent s'inscrire en ligne pour la conférence téléphonique. Les détails de la présentation et du webinaire seront disponibles dans la section Investisseurs du site de Roivant sous 'Événements et Présentations'. Une version archivée du webinaire sera accessible sur le site de l'entreprise après la conclusion de la conférence téléphonique.
Roivant (Nasdaq: ROIV) hat bekannt gegeben, dass am Donnerstag, den 8. August 2024, um 8:00 Uhr ET eine Live-Konferenzschaltung und ein Webcast stattfinden werden, um seine Finanzergebnisse für das am 30. Juni 2024 endende erste Quartal zu berichten und ein Geschäftsupdate zu geben. Interessierte Parteien können sich online für die Konferenzschaltung registrieren. Die Präsentations- und Webcast-Details werden im Investorenbereich der Roivant-Website unter 'Veranstaltungen & Präsentationen' verfügbar sein. Nach Abschluss der Konferenzschaltung wird eine archivierte Version des Webcasts auf der Unternehmenswebsite zugänglich sein.
- None.
- None.
BASEL, Switzerland and LONDON and NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 8, 2024, to report its financial results for the first quarter ended June 30, 2024, and provide a business update.
To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Roivant
Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Today, Roivant’s pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (“FcRn”) in development across several IgG-mediated autoimmune indications; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical stage molecules. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.
Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about potential share repurchases, the clinical and therapeutic potential of our products and product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our products and product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Roivant Investor Relations
ir@roivant.com
Media
Stephanie Lee
Roivant Sciences
stephanie.lee@roivant.com
FAQ
When will Roivant (ROIV) report its Q1 2024 financial results?
How can I access Roivant's (ROIV) Q1 2024 earnings call?
Where can I find the webcast details for Roivant's (ROIV) Q1 2024 earnings presentation?
Will Roivant (ROIV) provide a business update during its Q1 2024 earnings call?
